Literature DB >> 18295533

Relevance of experimental models for investigation of genotoxicity induced by antiretroviral therapy during human pregnancy.

Ofelia A Olivero1.   

Abstract

The current incidence of human immunodeficiency virus (HIV-1)/AIDS affects around 7000 pregnant women in the United States. When given during pregnancy, the nucleoside analog 3'-azido-3'-deoxythymidine (AZT) significantly reduces maternal-fetal transmission. It has been previously shown that AZT is incorporated into DNA, where it causes mutations in the HPRT and TK genes. It also changes cell cycle gene expression, and induces S-phase arrest, micronuclei, chromosomal aberrations, sister chromatid exchanges, telomeric attrition, and other genotoxic effects in cultured cells. A predicted consequence of these events is genomic instability that together, with clastogenicity may contribute to the carcinogenic potency of AZT. Various aspects of genotoxicity are explored in this contribution seeking to understand the multiple effects of this antiretroviral agent in animal models and humans. This mini-review describes some of the experimental models used to elucidate the genotoxicity induced by antiretroviral therapy during human pregnancy. The use of diverse methods to detect biomarkers of exposure, such as an AZT-specific radioimmunoassay, micronuclei bearing intact chromosomes, and telomeric DNA attrition highlight the role of in vitro models to elucidate exposure and risk. The relevance of the in vitro models is followed by the introduction of the role of the nucleoside analogs in transplacental carcinogenesis along with the description of a transplacental perfusion model and a transplacental carcinogenesis rodent model. In a more direct clinical application the use of AZT-DNA incorporation as a biomarker of exposure, in experiments conducted in vivo in Erythrocebus patas monkeys and in humans, addresses the possibility of elucidation of potential cancer risk in those infants exposed in utero. Two relevant aspects of this contribution are the potential application of some of the models described in this mini-review, as diagnostic tools in antiretroviral-exposed populations, and the use of these models to understand the nature of the genotoxicities and minimize the undesirable side effects of the antiretroviral therapy.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18295533      PMCID: PMC2447547          DOI: 10.1016/j.mrrev.2007.12.001

Source DB:  PubMed          Journal:  Mutat Res        ISSN: 0027-5107            Impact factor:   2.433


  26 in total

1.  Successes and challenges in the perinatal HIV-1 epidemic in the United States as illustrated by the HIV-1 Serosurvey of childbearing women.

Authors:  Lynne M Mofenson
Journal:  Arch Pediatr Adolesc Med       Date:  2004-05

2.  Genotoxicity and mitochondrial damage in human lymphocytic cells chronically exposed to 3'-azido-2',3'-dideoxythymidine.

Authors:  R P Agarwal; O A Olivero
Journal:  Mutat Res       Date:  1997-05-23       Impact factor: 2.433

Review 3.  Genetic risks of antiviral nucleoside analogues--a survey.

Authors:  P Wutzler; R Thust
Journal:  Antiviral Res       Date:  2001-02       Impact factor: 5.970

4.  Persistent mitochondrial dysfunction and perinatal exposure to antiretroviral nucleoside analogues.

Authors:  S Blanche; M Tardieu; P Rustin; A Slama; B Barret; G Firtion; N Ciraru-Vigneron; C Lacroix; C Rouzioux; L Mandelbrot; I Desguerre; A Rötig; M J Mayaux; J F Delfraissy
Journal:  Lancet       Date:  1999-09-25       Impact factor: 79.321

5.  Maternal viral load, zidovudine treatment, and the risk of transmission of human immunodeficiency virus type 1 from mother to infant. Pediatric AIDS Clinical Trials Group Protocol 076 Study Group.

Authors:  R S Sperling; D E Shapiro; R W Coombs; J A Todd; S A Herman; G D McSherry; M J O'Sullivan; R B Van Dyke; E Jimenez; C Rouzioux; P M Flynn; J L Sullivan
Journal:  N Engl J Med       Date:  1996-11-28       Impact factor: 91.245

6.  3'-azido-3'-deoxythymidine (AZT) transplacental perfusion kinetics and DNA incorporation in normal human placentas perfused with AZT.

Authors:  O A Olivero; R Parikka; M C Poirier; K Vähäkangas
Journal:  Mutat Res       Date:  1999-07-16       Impact factor: 2.433

7.  Progression elevated gene-3 (PEG-3) induces pleiotropic effects on tumor progression: modulation of genomic stability and invasion.

Authors:  Luni Emdad; Devanand Sarkar; Zao-Zhong Su; Habib Boukerche; Menashe Bar-Eli; Paul B Fisher
Journal:  J Cell Physiol       Date:  2005-01       Impact factor: 6.384

8.  Long-term exposure to zidovudine affects in vitro and in vivo the efficiency of phosphorylation of thymidine kinase.

Authors:  G Antonelli; O Turriziani; A Verri; P Narciso; F Ferri; G D'Offizi; F Dianzani
Journal:  AIDS Res Hum Retroviruses       Date:  1996-02-10       Impact factor: 2.205

9.  Transplacental effects of 3'-azido-2',3'-dideoxythymidine (AZT): tumorigenicity in mice and genotoxicity in mice and monkeys.

Authors:  O A Olivero; L M Anderson; B A Diwan; D C Haines; S W Harbaugh; T J Moskal; A B Jones; J M Rice; C W Riggs; D Logsdon; S H Yuspa; M C Poirier
Journal:  J Natl Cancer Inst       Date:  1997-11-05       Impact factor: 13.506

10.  Phosphorylation of 3'-azido-3'-deoxythymidine and selective interaction of the 5'-triphosphate with human immunodeficiency virus reverse transcriptase.

Authors:  P A Furman; J A Fyfe; M H St Clair; K Weinhold; J L Rideout; G A Freeman; S N Lehrman; D P Bolognesi; S Broder; H Mitsuya
Journal:  Proc Natl Acad Sci U S A       Date:  1986-11       Impact factor: 11.205

View more
  6 in total

1.  Impact of EMS outreach: successful developments in Latin America.

Authors:  Ofelia A Olivero; Marcelo Larramendy; Sonia Soloneski; Carlos F M Menck; Jaime Matta; Gustavo A Folle; Enrique Zamorano-Ponce; Graciela Spivak
Journal:  Environ Mol Mutagen       Date:  2010 Oct-Dec       Impact factor: 3.216

2.  Population approach to analyze the pharmacokinetics of free and total lopinavir in HIV-infected pregnant women and consequences for dose adjustment.

Authors:  Floris Fauchet; Jean-Marc Treluyer; Silvia M Illamola; Claire Pressiat; Gabrielle Lui; Elodie Valade; Laurent Mandelbrot; Jerome Lechedanec; Sandrine Delmas; Stéphane Blanche; Josiane Warszawski; Saik Urien; Roland Tubiana; Déborah Hirt
Journal:  Antimicrob Agents Chemother       Date:  2015-07-06       Impact factor: 5.191

Review 3.  HIV-exposed uninfected children: a growing population with a vulnerable immune system?

Authors:  L Afran; M Garcia Knight; E Nduati; B C Urban; R S Heyderman; S L Rowland-Jones
Journal:  Clin Exp Immunol       Date:  2014-04       Impact factor: 4.330

4.  Long-term exposure to AZT, but not d4T, increases endothelial cell oxidative stress and mitochondrial dysfunction.

Authors:  Erik R Kline; Leda Bassit; Brenda I Hernandez-Santiago; Mervi A Detorio; Bill Liang; Dean J Kleinhenz; Erik R Walp; Sergey Dikalov; Dean P Jones; Raymond F Schinazi; Roy L Sutliff
Journal:  Cardiovasc Toxicol       Date:  2008-12-09       Impact factor: 3.231

5.  Persistent metabolic changes in HIV-infected patients during the first year of combination antiretroviral therapy.

Authors:  N Chantal Peltenburg; Johannes C Schoeman; Jun Hou; Fernando Mora; Amy C Harms; Selwyn H Lowe; Jörgen Bierau; Jaap A Bakker; Annelies Verbon; Thomas Hankemeier; Andre Boonstra
Journal:  Sci Rep       Date:  2018-11-16       Impact factor: 4.379

Review 6.  Safety of protease inhibitors in HIV-infected pregnant women.

Authors:  Imène Chougrani; Dominique Luton; Sophie Matheron; Laurent Mandelbrot; Elie Azria
Journal:  HIV AIDS (Auckl)       Date:  2013-09-27
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.